Triumpharma LLC.

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. It has been growing at about 25.5% CAGR over the last 5 years and crossed the $1.9 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 69% of its revenue coming from global business.

Currently ranked 9th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology and Oncology in India. It is also known for its range of products in other hospital-based therapeutic segments in the EU and US.

Intas operates 15 formulation, R&D and distribution facilities, of which 10 are in India, and the rest in the UK and Mexico. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars and NDDS products.

Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies.

The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP certified manufacturing facility complemented with a GLP compliant QC lab.

Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces of our excellence.

ACROSS is the first truly global, agile CRO alliance. Offering cost effective, cutting edge innovative solutions for small/medium pharmaceutical and biotech companies as well as public health institutes and non-governmental organizations, ACROSS is the latest player on the global field of clinical trials.

ACROSS Global is an entirely new business model, providing enhanced and innovative global solutions through highly qualified, globally experienced, knowledgeable local experts. ACROSS Global identifies, analyses and mitigates risks across the entire clinical research spectrum, with an agility and focus to the envy of competitors. We provide value added solutions individually tailored for small and mid-size companies.

CMIC Group pioneered the CRO business in Japan over 28 years ago. Since then CMIC has continued as a leading innovator in the industry and has expanded services to encompass the entire pharmaceutical value-chain. We pride ourselves on meeting customers where they are and with exactly what they need to move their products forward.

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."